Cosmos Health Inc. Stock Price, News & Analysis

Cosmos Health (NASDAQ:COSM) reported a record quarter with revenue north of $17 million and expanding gross profit margins, marking the company's highest revenue in history on December 19, 2025. Management highlights operational scale across pharmaceuticals, nutraceuticals and healthcare services, plus manufacturing compliant with European GMP and established distribution.

The company completed acquisitions of ZipDoctor and Cloudscreen, CEO Greg Siokas continued share purchases, and Cosmos disclosed a $500,000 Ethereum purchase, bringing total digital investments to over $2 million under a $300 million facility.

Cosmos Health (NASDAQ:COSM) announced a long-term strategic partnership with Prime Ledger to digitally transform its financial operations and tokenize intellectual property. The agreement centers on Prime Ledger assisting to manage Cosmos Health’s $300,000,000 treasury, implementing controls, protocols, and reporting for Digital Asset Treasury (DAT) management, and deploying a token issuance platform for high-value IP assets. The collaboration includes integration with Conduit Network to consolidate on-chain and off-chain data for financial reporting, compliance, and real-time analytics. The initial phase begins in Q4 2025 and will focus on strategy, regulatory mapping, and platform architecture.

Cosmos Health (NASDAQ:COSM) announced that CEO Greg Siokas increased his stake during 2025, adding 3,398,055 shares year-to-date, including 301,101 shares bought between Nov 19–28, 2025. Following these purchases, his total ownership stands at 6,459,985 shares. The company noted record-breaking Q3 2025 results across revenue, gross profit, and gross margins but said its valuation remains under pressure. The release directs investors to Form 4 filings for transaction-level details such as ownership form, dates, amounts, and prices.

Cosmos Health (NASDAQ:COSM) reported record Q3 2025 results with revenue up 38% to $17.11M, gross profit up 116% to $2.60M, and a record gross margin of 15.21%. Adjusted EBITDA improved 74% to ($0.19M) and adjusted EPS narrowed to ($0.02) in Q3; nine-month adjusted EPS turned positive to $0.02. Cash rose sharply to $4.63M from $0.66M at June 30, 2025. The company secured a $300M digital financing facility and began Ethereum purchases, expanded U.S. operations for Sky Premium Life, and signed a contract manufacturing deal for MYCOFAGYL. Operating loss and GAAP net loss widened due to non-cash derivative and convertible-note charges.

Cosmos Health (NASDAQ:COSM) announced a new nanotechnology R&D program launched on October 31, 2025 to develop plant-based extract-loaded phytosomes for dietary supplements.

The program builds on the company’s CCX Hydrogel platform and aims to improve absorption, stability, and bioactivity of phytochemicals using a sustainable, solvent-free process suitable for nutraceutical formulation. Company leaders described the work as an effort to deliver next-generation, scientifically driven supplements with validated functional performance.

Cosmos Health (NASDAQ:COSM) announced on October 21, 2025 that it purchased an additional $200,000 of Ethereum (ETH), bringing its total ETH holdings to $2 million.

The acquisition was executed under the company’s existing $300 million digital assets facility, which the company says supports its strategy to diversify and strengthen its long‑term asset base through targeted digital asset investments.

Cosmos Health (NASDAQ:COSM) announced on October 16, 2025 that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the $1.00 minimum bid price requirement. Nasdaq confirmed the company’s closing bid price was at or above $1.00 for 18 consecutive business days from September 22, 2025 to October 15, 2025. As a result, Nasdaq has closed the matter and the Company is now in compliance with the listing rule. The company said this compliance was achieved organically and attributed to execution of strategic initiatives and strengthening fundamentals, and reiterated focus on shareholder value and its digital asset strategy.

Cosmos Health (NASDAQ:COSM) announced on October 13, 2025 that it purchased an additional $300,000 of Ethereum (ETH), bringing its total ETH holdings to $1.8 million. The purchase was executed under the company’s existing $300 million digital assets facility, which the company says supports its strategy to diversify holdings via strategic digital asset investments. Management reiterated commitment to continue the acquisition program under the financing facility.

Cosmos Health (NASDAQ:COSM) announced on October 10, 2025 that it purchased an additional $500,000 of Ethereum (ETH), bringing its total ETH holdings to $1.5 million. The purchase was executed under the company’s existing $300 million digital assets facility as part of a balance-sheet diversification strategy and to explore blockchain-enabled healthcare solutions. Management reiterated intent to continue using the financing facility and described digital assets as both long-term investments and potential enablers of decentralized healthcare applications.